Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298275 | 1.00 | KMT2A (0.40) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL26241247 | 0.92 | KMT2A (0.36) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL13313287 | 0.92 | KMT2A (0.36) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL8161008 | 0.82 | POLB (0.39) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL14380668 | 0.78 | KMT2A (0.33) | KMT2A | |
| SCHEMBL11586155 | 0.75 | MAPT (0.43) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL7283882 | 0.74 | SRC (0.50) | KMT2AMAPTMEN1L3MBTL1KDM4E | |
| SCHEMBL7283891 | 0.74 | SRC (0.50) | KMT2AMAPTMEN1L3MBTL1KDM4E | |
| SCHEMBL292606 | 0.73 | KMT2A (0.41) | KMT2AMAPTGLAHTR1AMEN1 | |
| SCHEMBL2092535 | 0.73 | KMT2A (0.41) | KMT2AMAPTGLAHTR1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7312244-B2 | Polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1698629-A2 | Polyamines and their use in therapy | Cellgate, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1177197-B1 | POLYAMINES AND THEIR USE IN THERAPY | CELLGATE INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1337504-A4 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | CELLGATE INC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794545-B1 | INCREASES IN THE POLYAMINE POOL SUPPRESS POLYAMINE BIOSYNTHESIS ALSO INHIBIT CELL GROWTH; ANTIPROLIFERATIVE AGENT | SLIL BIOMEDICAL CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040133013-A1 | Novel polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | SLIL BIOMEDICAL CORPORATION (US) | 2004-01-08 | — | — | US | disclosed |
| US-6649587-B1 | Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B | SLIL BIOMEDICAL CORPORATION | 2003-11-18 | — | — | US | disclosed |
| EP-1337504-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | Slil Biomedical Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002038105-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | SLIL BIOMEDICAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235962-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | KMT2A 376/4885MAPT 782/4885GLA 4226/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | KMT2A 376/4885MAPT 782/4885GLA 4226/4885 |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | KMT2A 2180/4885MAPT 3032/4885GLA 565/4885 |
| US-20040133013-A1 | Novel polyamine analog-amino acid conjugates useful as anticancer agents | SLC7A1, SRM, PAICS | KMT2A 419/4885MAPT 2646/4885GLA 3891/4885 |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | KMT2A 1702/4885MAPT 2473/4885GLA 616/4885 |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | KMT2A 2180/4885MAPT 3032/4885GLA 565/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | KMT2A 2180/4885MAPT 3032/4885GLA 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.